

# House File 520 - Introduced

HOUSE FILE 520

BY COMMITTEE ON PUBLIC SAFETY

(SUCCESSOR TO HSB 164)

## A BILL FOR

1 An Act relating to the medical use of cannabidiol including the  
2 scheduling of a cannabidiol investigational product approved  
3 as a prescription drug medication under federal law and  
4 including effective date provisions.

5 BE IT ENACTED BY THE GENERAL ASSEMBLY OF THE STATE OF IOWA:

1     Section 1. NEW SECTION. 124.201A Cannabidiol  
2     investigational product — rules.

3     1. If a cannabidiol investigational product approved as  
4     a prescription drug medication by the United States food and  
5     drug administration is eliminated from or revised in the  
6     federal schedule of controlled substances by the federal drug  
7     enforcement agency and notice of the elimination or revision  
8     is given to the board, the board shall similarly eliminate  
9     or revise the prescription drug medication in the schedule  
10    of controlled substances under this chapter. Such action by  
11    the board shall be immediately effective upon the date of  
12    publication of the final regulation containing the elimination  
13    or revision in the federal register.

14    2. The board shall adopt rules pursuant to chapter 17A  
15    to administer this section. The board may adopt rules on an  
16    emergency basis as provided in section 17A.4, subsection 3, and  
17    section 17A.5, subsection 2, to administer this section, and  
18    the rules shall be effective immediately upon filing unless  
19    a later date is specified in the rules. Any emergency rules  
20    adopted in accordance with this section shall also be published  
21    as a notice of intended action as provided in section 17A.4,  
22    subsection 1.

23    Sec. 2. REPEAL. Section 124D.8, Code 2017, is repealed.

24    Sec. 3. EFFECTIVE DATE. The section of this Act repealing  
25    section 124D.8, Code 2017, takes effect June 30, 2017.

26                                   EXPLANATION

27                   The inclusion of this explanation does not constitute agreement with  
28                   the explanation's substance by the members of the general assembly.

29    This bill relates to the medical use of cannabidiol,  
30    including the scheduling of a cannabidiol investigational  
31    product approved as a prescription drug medication under  
32    federal law.

33    The bill provides if a cannabidiol investigational product  
34    approved as a prescription drug medication by the United States  
35    food and drug administration is eliminated from or revised in

1 the federal schedule of controlled substances by the federal  
2 drug enforcement agency and notice of the elimination or  
3 revision is given to the board, the board of pharmacy shall  
4 similarly eliminate or revise the prescription drug medication  
5 in the schedule of controlled substances under Code chapter  
6 124. Such action by the board shall be immediately effective  
7 upon the date of publication of the final regulation containing  
8 the elimination or revision in the federal register.

9 The bill provides that the board shall adopt rules pursuant  
10 to Code chapter 17A to administer the bill and may adopt  
11 emergency rules which shall be effective immediately upon  
12 filing unless a later date is specified in the rules. Any  
13 emergency rules adopted shall also be published as a notice of  
14 intended action as provided in Code section 17A.4, subsection  
15 1.

16 The bill strikes the repeal of Code chapter 124D (medical  
17 cannabidiol Act) before the repeal becomes effective July 1,  
18 2017.